Publication date: July 2018
Source:Biomedicine & Pharmacotherapy, Volume 103
Author(s): Mohammad Hasan Soheilifar, Ramezan Ali Taheri, Reza Zolfaghari Emameh, Abdolvahab Moshtaghian, Hamid Kooshki, Mohammad Reza Motie
Alveolar soft part sarcoma (ASPS) is a highly aggressive rare soft tissue sarcoma (STS) with poor prognosis especially in the metastatic form. ASPS is resistant to standard chemotherapy. Although, early diagnosis and surgical resection of operable tumor could lead to improved patient survival but novel treatment options are needed for advanced (metastatic) ASPS. This malignancy exhibits highly angiogenic behavior which reflects hyper-activation and over expression of angiogenic factors. Understanding the molecular events in this type of sarcoma is important in finding novel molecular based targeted therapies. We aim to review molecular aspects of ASPS growth and treatment.
Graphical abstract
https://ift.tt/2Hpvjmk
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου